New drug cocktail shows promise for tough lung cancer after chemo fails
NCT ID NCT05001971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, anlotinib and penpulimab, in 65 patients with small cell lung cancer whose disease had worsened after initial platinum-based chemotherapy. Anlotinib blocks blood vessel growth to tumors, while penpulimab helps the immune system attack cancer cells. The goal was to see if this combo could shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anlotinib and Penpulimab
What this could lead to
If successful, this combination could offer a new second-line treatment option for patients with small cell lung cancer whose disease has progressed after initial chemotherapy.
What could go wrong
This is a small, single-arm phase 2 pilot study with no placebo or comparison group, so results may not be definitive. Side effects from the drug combination are possible, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nong Yang
Changsha, Hunan, 410000, China